EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY 4.0

Efficacy and Safety of Lactobacillus delbrueckii subsp. lactis CKDB001 Supplementation on Cognitive Function in Mild Cognitive Impairment: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Hyang-Im Baek iD, So-Young Kwon iD, Hye-Ji Noh, Su Young Son iD, Jong Cheon Joo, Soo Jung Park iD

Nutrients · 21.10.2025 · 17 (20) · 3313

DOI: 10.3390/nu17203313 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Nutrients, online erschienen am 21.10.2025. Verfasst von Hyang-Im Baek und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Food Science & Nutrition, Woosuk University, Wanju 55338, Republic of Korea. Hauptthemen laut MEDLINE: Cognitive Dysfunction, Probiotics, Cognition, Lactobacillus delbrueckii. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Education, This clinical study was funded by Chong Kun Dang Bio Corporation and Genome & Company. The authors acknowledge the support of the Regional Innovation System &…, Chong Kun Dang Bio Corporation and Genome & Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Modulation of the gut–brain axis using probiotics present a promising approach for enhancing cognitive function in mild cognitive impairment (MCI). In prior non-clinical research, Lactobacillus delbrueckii subsp. lactis CKDB001 (LL) exhibited potential to enhance cognitive function. We therefore conducted a clinical trial to assess the efficacy and safety of LL supplementation in MCI.

Methods

A 12-week, randomized, double-blind, placebo-controlled, multi-center trial was performed in 100 participants aged 55–80 years. Subjects were randomly assigned to receive LL (n = 50, 5.0 × 109 CFU/day) or placebo (n = 50). Efficacy and safety were evaluated at baseline and after 12 weeks.

Results

LL supplementation resulted in significantly greater improvements than placebo in the Alzheimer’s Disease Assessment Scale–Cognition 13 total score, the memory sub-score, reaction time for Part A of the Trail Making Test, and word/color reaction times on the Stroop test. Taxonomic and metabolomic profiling of fecal samples showed significantly greater changes in the relative abundance of beneficial microorganisms in the LL group, with the most pronounced shifts at the family (Lactobacillaceae, Bifidobacteriaceae) and genus (Lactobacillus) levels. In addition, the LL group exhibited significantly higher fecal levels of indole-derived metabolites, including 5-hydroxyindole-3-acetic acid, indole-3-lactic acid, and indole-3-glycol. Safety assessments indicated LL was safe and well-tolerated, with no clinically relevant changes in laboratory findings or adverse events.

Conclusions

These findings suggest that LL supplementation may enhance cognitive function in MCI by modulating the gut–brain axis through effects on gut microbiota and related metabolites, and could serve as a safe functional food to support cognitive health.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cognitive DysfunctionProbioticsCognitionLactobacillus delbrueckiiDietary SupplementsHumansDouble-Blind MethodAgedMaleFemaleMiddle AgedAged, 80 and overGastrointestinal MicrobiomeTreatment OutcomeFeces

Stichwörter der Autor:innen

Lactobacillus delbrueckii subsp. lactis CKDB001clinical trialcognitive functionfunctional foodmild cognitive impairmentprobiotics

Autor:innen und Institutionen

  • Department of Food Science & Nutrition, Woosuk University, Wanju 55338, Republic of Korea.
  • Research Institute, Chong Kun Dang Bio (CKD Bio), Seoul 03742, Republic of Korea.
  • Genome & Company, Suwon 16229, Republic of Korea.
  • Department of Sasang Constitutional Medicine, College of Korean Medicine, Wonkwang University, Iksan 54538, Republic of Korea.
  • Department of Sasang Constitutional Medicine, College of Korean Medicine, Woosuk University, Jeonju 55338, Republic of Korea.

ORCID-Profile: Hyang-Im Baek, So-Young Kwon, Su Young Son, Soo Jung Park

Förderung

  • Ministry of Education
  • This clinical study was funded by Chong Kun Dang Bio Corporation and Genome & Company. The authors acknowledge the support of the Regional Innovation System &…
  • Chong Kun Dang Bio Corporation and Genome & Company
  • Jeonbuk State, Republic of Korea

Zitieren

APA

Baek, H. I., Kwon, S. Y., Noh, H. J., Son, S. Y., Joo, J. C., & Park, S. J. (2025). Efficacy and Safety of Lactobacillus delbrueckii subsp. lactis CKDB001 Supplementation on Cognitive Function in Mild Cognitive Impairment: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Nutrients, 17(20), 3313. https://doi.org/10.3390/nu17203313

Vancouver

Baek HI, Kwon SY, Noh HJ, Son SY, Joo JC, Park SJ. Efficacy and Safety of Lactobacillus delbrueckii subsp. lactis CKDB001 Supplementation on Cognitive Function in Mild Cognitive Impairment: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Nutrients. 2025;17(20):3313. doi:10.3390/nu17203313

BibTeX
@article{Baek2025,
  author = {Baek, Hyang-Im and Kwon, So-Young and Noh, Hye-Ji and Son, Su Young and Joo, Jong Cheon and Park, Soo Jung},
  title = {Efficacy and Safety of Lactobacillus delbrueckii subsp. lactis CKDB001 Supplementation on Cognitive Function in Mild Cognitive Impairment: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial},
  journal = {Nutrients},
  year = {2025},
  volume = {17},
  number = {20},
  pages = {3313},
  doi = {10.3390/nu17203313}
}
Kostenlos starten →